In June, a study supported by the National Cancer Institute found that for people with HIV, early treatment of precancerous anal lesions caused by human papillomavirus (HPV) can cut rates of anal cancer incidence by more than half. These findings from the Anal Cancer/HSIL Outcomes Research (ANCHOR) study are creating secondary prevention options for those at risk for anal cancer who have not received the HPV vaccine. We look into the history of the study and what its work means for those at risk for anal cancer.
Cancer HealthCast
47m listen
An Intersectional Look at Anal Cancer and HIV
Share
NCI’s ANCHOR study discovered that early treatment of precancerous lesions can cut anal cancer rates by more than half in people with HIV.
-
Dr. Joel Palefsky Professor of Medicine University of California San Francisco -
Dr. Robert Yarchoan Director, Office of HIV and AIDS Malignancy NCI
Related Content
-
Marne Innovation Center Empowers Soldiers to Solve Battlefield Challenges
The Army’s Marne Innovation Center is transforming battlefield efficiency by sourcing real-time problems and solutions directly.
12m listen -
From Fed to Founder: Joe Scheidler on People, Policy, Innovation
Joe Scheidler outlined lessons from his White House and State Department tenure that helped drive his startup success.
7m watch -
IHS Modernizes Native Health Care with PATH EHR
IHS CIO Mitchell Thornbrugh shares how PATH EHR is transforming Native health care through data liberation, scalable systems and community-driven innovation.
18m listen -
From FedRAMP to Industry: Tips for Successful Career Transitions
Former FedRAMP head Brian Conrad discusses his transition experiences from government and industry to continue serving the mission.
6m watch
